MA52274A - Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse - Google Patents

Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse

Info

Publication number
MA52274A
MA52274A MA052274A MA52274A MA52274A MA 52274 A MA52274 A MA 52274A MA 052274 A MA052274 A MA 052274A MA 52274 A MA52274 A MA 52274A MA 52274 A MA52274 A MA 52274A
Authority
MA
Morocco
Prior art keywords
epidermolysis
coenzyme
bubble
formulations
prevention
Prior art date
Application number
MA052274A
Other languages
English (en)
Inventor
Michael Andrew Kiebish
Niven Rajin Narain
Rangaprasad Sarangarajan
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MA52274A publication Critical patent/MA52274A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052274A 2017-05-17 2018-05-16 Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse MA52274A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762507773P 2017-05-17 2017-05-17

Publications (1)

Publication Number Publication Date
MA52274A true MA52274A (fr) 2021-02-24

Family

ID=64274898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052274A MA52274A (fr) 2017-05-17 2018-05-16 Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse

Country Status (12)

Country Link
US (2) US11419830B2 (fr)
EP (1) EP3634391A4 (fr)
JP (1) JP7173992B2 (fr)
KR (1) KR20200015549A (fr)
CN (1) CN110769818A (fr)
AU (1) AU2018269377A1 (fr)
BR (1) BR112019024116A2 (fr)
CA (1) CA3063916A1 (fr)
CL (1) CL2019003287A1 (fr)
MA (1) MA52274A (fr)
MX (1) MX2023004618A (fr)
WO (1) WO2018213502A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022366945A1 (en) 2021-10-12 2024-05-23 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588010A (ja) 1981-07-08 1983-01-18 Eisai Co Ltd ユビデカレノン含有リポソ−ム
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPS6277318A (ja) 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
JPS6339813A (ja) 1986-08-05 1988-02-20 Eisai Co Ltd 創傷治療剤
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5863556A (en) 1993-08-20 1999-01-26 Euro-Celtique, S.A. Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
BR9509590A (pt) 1994-11-04 1997-12-23 Polymun Scient Immunbio Forsch Aplicação de sod em liposomas
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
EP1009383A1 (fr) 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Systeme d'administration par voie orale au moyen de liposomes
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US20040170625A1 (en) 1998-07-30 2004-09-02 Regenerx Biopharmaceuticals, Inc. Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
DE19905879A1 (de) 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Ubichinon Qn zur Behandlung von Schmerzen
US20050019268A1 (en) 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000057871A2 (fr) * 1999-03-30 2000-10-05 Purdue Research Foundation Procedes d'identification d'agents inhibant des facteurs seriques du vieillissement, utilisations et compositions associees
US20020048551A1 (en) 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
IT1307281B1 (it) 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
GB2360706B (en) 2000-02-09 2002-07-17 Paul A Sneed Treatment of fibromyalgia with ubiquinone 10 and succinic acid
WO2001082899A2 (fr) 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Agents de diagnostic cationique, d'imagerie et de therapie associes a des sites vasculaires actives
ATE402692T1 (de) * 2000-05-09 2008-08-15 Kaneka Corp Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
US6465517B1 (en) 2000-07-11 2002-10-15 N.V. Nutricia Composition for the treatment of migraine
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US6984395B2 (en) 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
AU2002309038B2 (en) 2001-05-10 2007-05-17 Kaneka Corporation Compositions for transmucosal administration containing coenzyme Q as the active ingredient
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US9034310B2 (en) 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
WO2003075900A2 (fr) 2002-03-09 2003-09-18 Mse Pharmazeutika Gmbh Utilisation d'ubiquinones pour influencer l'effet de l'histamine
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
TWI322008B (en) 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
CN1208052C (zh) 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
US8252322B2 (en) 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
RU2006101991A (ru) 2003-06-25 2006-06-27 Чарлз ЭРВИН (US) Химическая композиция и способ увеличения подачи кофермента q10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20070009583A1 (en) 2003-10-10 2007-01-11 Qvist Michael H Dressing
ME01881B (fr) 2004-01-22 2014-12-20 Univ Miami Formulations topiques de coenzyme q10 et procedes d'utilisation
US20050226947A1 (en) * 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
US20050208118A1 (en) 2004-03-18 2005-09-22 Takemoto Arnold C Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals
EP1784193A4 (fr) 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd Composition et procede pour le traitement et la prevention de l'atherosclerose
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
EP1909763A2 (fr) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones a biodisponibilite amelioree
JP2007063160A (ja) 2005-08-30 2007-03-15 Shiseido Co Ltd 基底膜安定化剤
ES2836184T3 (es) 2006-05-02 2021-06-24 Univ Miami Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
ES2755840T3 (es) 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
JP2009040757A (ja) 2007-08-10 2009-02-26 Maruzen Pharmaceut Co Ltd ラミニン５産生促進剤、皮膚基底膜正常化剤及び皮膚損傷回復促進剤
JP2009191039A (ja) 2008-02-15 2009-08-27 Maruzen Pharmaceut Co Ltd ヒアルロン酸合成酵素３ｍＲＮＡ発現促進剤、アクアポリン３ｍＲＮＡ発現促進剤、セリンパルミトイルトランスフェラーゼｍＲＮＡ発現促進剤及びラミニン５産生促進剤
CA2761717A1 (fr) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methodes de traitement de maladies oncologiques a l'aide de decaleurs epimetaboliques, de molecules intracellulaires multidimensionnelles ou d'influenceurs environnementaux
IN2012DN01911A (fr) * 2009-08-25 2015-07-24 Cytotech Labs Llc
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
KR101947126B1 (ko) 2010-12-28 2019-02-13 카메디스 리미티드 감염의 치료 및 예방을 위한 식물 추출물
US9211256B2 (en) 2011-03-08 2015-12-15 The Johns Hopkins University Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
WO2013181639A1 (fr) 2012-06-01 2013-12-05 Berg Pharma Llc Traitement de tumeurs solides au moyen de la coenzyme q10
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物

Also Published As

Publication number Publication date
WO2018213502A1 (fr) 2018-11-22
EP3634391A1 (fr) 2020-04-15
BR112019024116A2 (pt) 2020-06-02
MX2023004618A (es) 2023-05-09
KR20200015549A (ko) 2020-02-12
JP7173992B2 (ja) 2022-11-17
CA3063916A1 (fr) 2018-11-22
CL2019003287A1 (es) 2020-07-31
CN110769818A (zh) 2020-02-07
US20230142060A1 (en) 2023-05-11
US11419830B2 (en) 2022-08-23
EP3634391A4 (fr) 2021-02-24
US20180369164A1 (en) 2018-12-27
JP2020520927A (ja) 2020-07-16
AU2018269377A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
IL271492A (en) Use of cannabidiol in the treatment of multiple sclerosis complex
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
PT3576738T (pt) Utilização de gaboxadol no tratamento do zumbido
IL258064A (en) Devices enabling the disabled to stand, walk and activate one's body
FR2999428B1 (fr) Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses
EP3344632A4 (fr) Composés hétérobicycliques de pyrimidinone et leur utilisation dans le traitement de troubles médicaux
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
IL268144A (en) Targeted Segregation Assisted Lipid Mediators for Use in the Treatment of Neurodegenerative and/or Autoimmune Diseases
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
MA52274A (fr) Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
FR3035326B1 (fr) Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
MA44769A (fr) Formulations destinées à une utilisation dans le traitement ou la prévention de maladies urologiques
MA46519A (fr) Dérivé d'oxazine destiné à être utilisé dans le traitement ou la prévention de l'angiopathie amyloïde cérébrale
MA45678A (fr) Utilisation du xibornol en tant qu'agent actif dans le traitement d'infections virales
ES1202037Y (es) Aparato de rescate para animales y personas en balsas de agua u otros tipos de liquidos
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
GB201700827D0 (en) Specialized pro-resolving lipid mediators for use in the treatment of neurodegenerative diseases and/or autoimmune diseases
IL261240B (en) Preparations useful in the prevention and/or treatment of inflammation and pain
HK1219880A1 (zh) 高氧水在製備用於治療和/或預防高尿酸血症的藥物的用途